Abstract
To our readers:With deep regrets, we inform our Readers that the article Challenges of combined everolimus/endocrine therapy in hormone receptor-positive metastatic breast cancer (DOI: http://dx.doi.org/10.4081/oncol.2014.236), which has been published Ahead of Print in the first issue of Oncology Reviews (2014), contains verbatim text plagiarized from another paper.1The manuscript must be considered as retracted. On behalf of the Editorial Board of Oncology Reviews, I apologize to the Author of the manuscript whose text was plagiarized by Y. Abubakr and Y. Albushra that this was not picked up in the peer review process. I also apologize to the affected journal for the violation of copyright due to plagiarism. Oncology Reviews is uncompromising in its commitment to scientific integrity. When credible evidence of misconduct is brought to our attention, our commitment to the scientific record and to our readership requires immediate notification. Oncology Reviews is increasingly employing sophisticated software to detect plagiarism. Other journals use similar tools. Authors should be aware that most journals routinely employ plagiarism detection software, and that any plagiarism is likely to be detected.Camillo Porta, Editor-in-Chief Oncology Reviews Reference 1. André F. Enhancing effectiveness of endocrine therapy in hormone receptor-positive advanced breast cancer. Medscape Education Oncology. CME Released: 05/24/2013; Valid for credit through 05/24/2014. http://www.medscape.org/viewarticle/804496
Highlights
On behalf of the Editorial Board of Oncology Reviews, I apologize to the Author of the manuscript whose text was plagiarized by Y
Oncology Reviews is uncompromising in its commitment to scientific integrity
Authors should be aware that most journals routinely employ plagiarism detection software, and that any plagiarism is likely to be detected
Summary
Camillo Porta IRCCS San Matteo University Hospital Foundation, Pavia, Italy To our readers: With deep regrets, we inform our Readers that the article Challenges of combined everolimus/endocrine therapy in hormone receptor-positive metastatic breast cancer
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.